Adding Bismuth to Rabeprazole-Based First-Line Triple Therapy Does Not Improve the Eradication of Helicobacter pylori

Table 5

Univariate analysis of clinical factors which might influence the efficacy of the RAK and RBAK.

Eradication rate, n/N (%)	RAK	RBAK	value
Resistance to
Metronidazole
ITT and PP	6/11 (54.5)	7/11 (63.6)	1.00
Clarithromycin
ITT and PP	2/5 (40.0)	1/5 (20.0)	1.00
Tetracycline	—	—	—
Levofloxacin	3/3 (100)	3/6 (50.0)	0.46
Amoxicillin	1/1 (100)	1/1 (100)	1.00
Dual resistance^¶
Present
ITT	3/5 (60.0)	3/5 (60.0)	1.00
PP	3/5 (60.0)	3/4 (75.0)	1.00
Absent
ITT	27/33 (81.8)	27/38 (71.1)	0.29
PP	27/31 (87.1)	27/35 (77.1)	0.30
Adverse events
Present	25/36 (69.4)	34/41 (82.9)	0.16
Absent	31/40 (77.5)	29/40 (72.5)	0.61
Compliance
Good	58/80 (72.5)	63/81 (77.8)	0.44
Poor	1/1 (100)	0/0 (0.0)	—
Smoking
Present	17/23 (73.9)	15/20 (75.0)	0.94
Absent	42/58 (72.4)	48/61 (78.7)	0.42

Fisher exact test. ^¶Dual resistance was defined as presence of any two of the five antibiotics.